American Urological Association Releases New Guideline on Genitourinary Syndrome of Menopause
BALTIMORE, April 28, 2025 (GLOBE NEWSWIRE) — Today, the American Urological Association (AUA) released the 2025 Guideline on the Genitourinary Syndrome of Menopause.
This Guideline covers the evaluation and treatment of women who present to a clinician with symptoms and signs of genitourinary syndrome of menopause (GSM). GSM describes the spectrum of symptoms and physical changes resulting from declining estrogen and androgen concentrations in the genitourinary tract during perimenopause and after menopause. Since the introduction of the term GSM in 2014, no consensus has been reached about the number or type of symptoms (i.e., vulvovaginal, urinary, sexual) needed to diagnose GSM, nor a requirement for identifying concurrent physical signs.
This guideline endeavors to provide clinicians with information regarding identification, diagnosis, counseling and treatment for patients with GSM to optimize symptom control and improve quality of life while minimizing adverse effects. The strategies defined in this document were derived from evidence-based and consensus-based processes.
'This GSM guideline provides pragmatic statements designed for rapid implementation, which promises to be transformational for both engagement of urologists in evaluation and treatment as well as improvement of patient outcomes,' said Dr. Melissa Kaufman, chair of the Guideline. 'On behalf of the millions of patients who will benefit from this landmark document, we wish to express our deep appreciation to the American Urological Association for the courageous decision to sponsor development of this Guideline.'
This Guideline has 26 recommendations and is a valuable reference for effective evidence-based care in relation to GSM.
This Guideline includes: Guidance on the screening, evaluation and physical exam of patients who present with GSM symptoms and signs.
Evidence-based guidance on hormonal and non-hormonal treatment options, including local, low-dose vaginal estrogen.
A framework for the proper surveillance of GSM patients who undergo hormonal-based treatment and the follow-up of all GSM patients who undergo any kind of therapy to alleviate symptoms.
'One of the most rewarding parts of my clinical practice has been helping patients improve their quality of life by addressing symptoms of GSM. Through scientific evidence and the application of shared decision making, this AUA guideline will help clinicians educate, empower and treat patients with GSM,' notes Dr. Una Lee, vice-chair of the Guideline. 'By promoting high-quality information and dispelling myths and misinformation, clinicians can counsel patients with confidence with the ultimate goal of elevating the urologic care we provide.'
The 2025 Guideline on the Genitourinary Syndrome of Menopause was produced in partnership with Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) and American Urogynecologic Society (AUGS) and was endorsed by The International Society for the Study of Women's Sexual Health (ISSWSH) and The Menopause Society (TMS).
The full guideline is now available at https://www.AUAnet.org/GSMguideline
About the American Urological Association: Founded in 1902 and headquartered near Baltimore, Maryland, the American Urological Association is a leading advocate for the specialty of urology, and has more than 26,000 members throughout the world. The AUA is a premier urologic association, providing invaluable support to the urologic community as it pursues its mission of fostering the highest standards of urologic care through education, research and the formulation of health policy.
Attachment
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
FDA Approves Expanded Indication for AJOVY® (fremanezumab-vfrm), The First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine
FDA approves single-dose AJOVY® (fremanezumab-vfrm) injection for the preventive treatment of episodic migraine in children and adolescents aged 6-17 who weigh 45 kilograms or more, offering a long-awaited monthly treatment option with in-office or at-home administration1 AJOVY expands access across age groups as the first and only calcitonin gene-related peptide (CGRP) antagonist approved for pediatric episodic migraine prevention and migraine prevention in adults1 This approval marks an important step in expanding the impact of AJOVY beyond adults since its U.S. approval in 2018, and underscores Teva's ongoing efforts to advance and address neurological challenges2 PARSIPPANY, N.J. and TEL AVIV, Israel, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today that the U.S. Food and Drug Administration (FDA) has approved AJOVY for the preventive treatment of episodic migraine in children and adolescent patients aged 6-17 years who weigh 45 kilograms (99 pounds) or more. With this approval, AJOVY becomes the first and only calcitonin gene-related peptide (CGRP) antagonist indicated for the preventive treatment of episodic migraine in pediatric patients and migraine in adults, marking a meaningful advancement in expanding preventive treatment options for those living with migraine. Preventative treatment can help reduce the frequency of migraine attacks, helping children and adolescents to better manage the condition day-to-day. AJOVY is administered once a month and available for in-office or at home use, offering a treatment option that is intended to support adherence and reduce treatment burden for families.1 'Migraines are a common yet invisible condition that can severely disrupt daily life for children and adolescents, often leaving them overlooked and misunderstood,' said Chris Fox, Executive Vice President, U.S. Commercial and Innovative Franchise Lead and Head of Global Marketing Business at Teva. 'With this FDA approval, AJOVY now offers younger patients a new treatment option, addressing a long-standing gap in care and offering families added support as they navigate the challenges of this condition.' 1 in 10 children and adolescents in the U.S. suffer from migraine, one of the most common and disabling neurological conditions.3 Despite its widespread prevalence, pediatric migraine is often underrecognized and undertreated, contributing to missed school days, difficulties with schoolwork, and disrupted social activities.4 "Pediatric migraine is a complex condition that can significantly impact a child's daily life, from school performance to emotional well-being," said Dr. Jennifer McVige, MD, MA, Pediatric Neurologist at the DENT Neurologic Institute. 'Having an FDA-approved treatment like AJOVY offers an important option, providing a targeted approach to preventive treatment for episodic migraine that can help reduce the frequency of attacks in younger patients and help clinicians manage this often-overlooked condition.' Building on its established success in adult patients since its U.S. approval in 2018, this expanded indication strengthens Teva's commitment to broadening access to neuroscience therapies across age groups.2 AJOVY continues to demonstrate efficacy in addressing the underlying biology of migraine and now provides a treatment pathway for a patient population with historically limited preventive options. About MigraineMigraine attacks cause disabling pain, nausea, vomiting and sensitivities to light and sound, resulting in serious effects on the ability to complete daily tasks.5 Migraine can cause significant disability in children and adolescents, leading to absence from school, impaired educational performance and missed social activities.3 About AJOVYAJOVY is indicated for preventive treatment of migraine in adults and episodic migraine in children and adolescent patients aged 6-17 years who weigh 45 kilograms (99 pounds) or more. AJOVY is available as a 225 mg/1.5 mL single dose injection in a pre-filled autoinjector or in a pre-filled syringe. AJOVY can be administered either by a healthcare professional or at home by a patient or caregiver. No starting dose is required to begin treatment. For full prescribing information, visit INDICATION AND USAGE AJOVY is indicated for: the preventive treatment of migraine in adults, and the preventive treatment of episodic migraine in pediatric patients who are 6 to 17 years of age and who weigh 45 kg or more. IMPORTANT SAFETY INFORMATION Contraindications: AJOVY is contraindicated in patients with serious hypersensitivity to fremanezumab-vfrm or to any of the excipients. Reactions have included anaphylaxis and angioedema. Hypersensitivity Reactions: Hypersensitivity reactions, including rash, pruritus, drug hypersensitivity, and urticaria were reported with AJOVY in clinical trials. Most reactions were mild to moderate, but some led to discontinuation or required corticosteroid treatment. Most reactions were reported from within hours to one month after administration. Cases of anaphylaxis and angioedema have been reported in the postmarketing setting. If a hypersensitivity reaction occurs, consider discontinuing AJOVY and institute appropriate therapy. Hypertension: Development of hypertension and worsening of pre-existing hypertension have been reported following the use of CGRP antagonists, including AJOVY, in the postmarketing setting. Monitor patients treated with AJOVY for new-onset hypertension or worsening of pre-existing hypertension, and consider whether discontinuation of AJOVY is warranted. Raynaud's Phenomenon: Development of Raynaud's phenomenon and recurrence or worsening of pre-existing Raynaud's phenomenon have been reported in the postmarketing setting following the use of CGRP antagonists, including AJOVY. Many of the cases reported serious outcomes, including hospitalizations and disability, generally related to debilitating pain. AJOVY should be discontinued if signs or symptoms of Raynaud's phenomenon develop. Patients with a history of Raynaud's phenomenon should be monitored for, and informed about the possibility of, worsening or recurrence of signs and symptoms. Adverse Reactions: The most common adverse reactions in clinical trials (≥5% and greater than placebo) were injection site reactions. Please click here for full U.S. Prescribing Information for AJOVY (fremanezumab-vfrm) injection. About TevaTeva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva's commitment has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients' needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit Cautionary Note Regarding Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management's current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as 'should,' 'expect,' 'anticipate,' 'estimate,' 'target,' 'may,' 'project,' 'guidance,' 'intend,' 'plan,' 'believe' and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully develop and commercialize AJOVY (fremanezumab) for the prevention of episodic migraine in children and adolescents; our ability to successfully compete in the marketplace including our ability to develop and commercialize additional pharmaceutical products; our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development; and other factors discussed in this press release, in our Quarterly Report on Form 10-Q for the second quarter of 2025 and in our Annual Report on Form 10-K for the year ended December 31, 2024, including in the section captioned 'Risk Factors.' Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements. AJOVY (fremanezumab-vfrm) injection, for subcutaneous use. Current Prescribing Information. Parsippany, NJ. Teva Neuroscience, Inc. Data on file. Parsippany, NJ: Teva Neuroscience, Inc. Al Khalili Y, Asuncion RMD, Chopra P. Migraine Headache in Childhood. [Updated 2023 Mar 4]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: Pediatric Migraine, An Update. Greene, Kaitlin. et al; Neurology clinics, Volume 37, Issue 4, 815-833. August 31, 2019. Jaimie D Steinmetz, Katrin Seeher, Nicoline Schiess, Emma Nichols, Bochen Cao, Chiara Servili, Vanessa Cavallera, Christopher J L Murray, Kanyin Liane Ong, Valery L Feigin, Theo Vos, and Tarun Dua on behalf of the GBD network. Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis of the Global Burden of Disease Study 2021. Lancet Neurol. (in press). Teva Media Inquiries:TevaCommunicationsNorthAmerica@ Teva Investor Relations InquiresTevaIR@
Business Upturn
3 hours ago
- Business Upturn
Global Medical Aesthetic Devices Market to Reach $37.9 Billion by 2029
Boston, Aug. 06, 2025 (GLOBE NEWSWIRE) — As global demand for aesthetic enhancement rises, medical aesthetic devices are transforming how patients approach cosmetic care. From laser-based treatments to minimally invasive procedures, leading companies such as AbbVie, Alma Lasers, and Johnson & Johnson to invest in next-generation technologies to meet patient expectations for precision, safety, and recovery time. According to the report, the growing adoption of non-invasive techniques, rapid advances in cosmetic laser systems, and the rise in medical tourism are redefining treatment standards. The global market is projected to grow at a CAGR of 11.3% from 2024 to 2029. As North America maintains its leadership and Europe rapidly scales access to aesthetic treatments, manufacturers must navigate strict regulatory frameworks, ensure clinical efficacy, and address affordability to realize the sector's full potential. Market Overview: Key Insights and Forecast BCC Research's latest report, Medical Aesthetic Devices: Technologies and Global Markets, offers a comprehensive assessment of the evolving aesthetics landscape. It explores innovations across laser systems, breast implants, body contouring tools, and injectables, while also examining demand trends by age group, geographic region, and treatment type. The global market for medical aesthetic devices was valued at $20.1 billion in 2023 and is projected to reach $37.9 billion by the end of 2029. The report delivers forward-looking insights based on past sales trends, device approvals, clinical trial momentum, and regional adoption patterns. It segments the market by device type, application, and end user, supported by data- intensive analysis of market size, product strategies, and regional shifts. Market Leadership in Transition The competitive landscape is evolving as companies scale energy and non-energy-based devices to support dermatological, surgical, and body contouring applications. Non-energy-based aesthetic devices—such as breast implants and dermal fillers—are expected to dominate the market by value through 2029. Companies such as Bausch Health Companies, Merz Pharma, and S.p.A. are advancing proprietary solutions aimed at scar reduction, wrinkle treatment, and facial rejuvenation. These companies are expanding regionally and leveraging partnerships for clinical validation and faster approvals (Chapter 7: Competitive Intelligence). Emerging Technologies and Investment Trends Technology is pushing the boundaries of aesthetic medicine. Robotic-assisted procedures, AI-guided skin diagnostics, and plasma-based skin therapies are expanding the range of possibilities for clinicians and patients alike. Startups such as Nova Plasma Ltd. and InMode are entering the field with breakthrough platforms targeting both safety and personalization. These shifts are driving fresh investments and accelerating product development cycles—particularly in light-based therapies and microfocused ultrasound applications (Chapter 5: Emerging Technologies and Developments). Pipeline Assessment and Applications Device manufacturers are investing heavily in next-gen solutions that blur the lines between cosmetic and therapeutic care. Procedures such as non-surgical body contouring and RF microneedling are expanding beyond traditional beauty centers and entering mainstream healthcare environments. Procedures for anti-aging, facial sculpting, and skin resurfacing are leading R&D investment, with a strong pipeline of multi-modal platforms that offer real-time feedback and adaptable energy delivery (Chapter 6: Market Segmentation Analysis). Regulatory and Access Challenges Regulatory bodies in the U.S., EU, and Asia are tightening controls around efficacy claims, clinical performance, and safety data. From FDA approvals to CE mark certifications, device manufacturers must maintain ongoing compliance for sustained market presence. Countries such as Japan, China, and Saudi Arabia are building tailored frameworks to govern the fast-evolving aesthetics space. Meanwhile, fragmented reimbursement policies and variable access in emerging economies continue to challenge equitable adoption (Chapter 4: Industry Outlook: Regulatory Framework). Strategic Outlook: The Road Ahead As the medical aesthetics field evolves, manufacturers are intensifying efforts to enhance procedural precision, minimize recovery time, and offer patient-specific outcomes. This includes innovations in ergonomic device design, non-invasive treatment delivery, and seamless clinical workflow integration (Chapter 7: Competitive Intelligence). In parallel, sustainability efforts are gaining traction across the value chain. From reduced material waste, greener energy consumption, and lifecycle-conscious device design to energy-efficient R&D practices, these priorities are increasingly being embedded into product development and procurement strategies. Firms aligning innovation with ESG values are better positioned to lead the next wave of responsible growth (Chapter 9: Sustainability in the Medical Aesthetic Device Industry; Chapter 7: Competitive Intelligence). Report Synopsis Report Metric Details Base year considered 2023 Forecast period considered 2024-2029 Base year market size $20.1 billion Market size forecast $37.9 billion Growth rate CAGR of 11.3% for the forecast period of 2024-2029 Segments covered Device Type, Application, End User, and Region Regions covered North America, Europe, Asia-Pacific and the Rest of the World (RoW) Countries covered U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Japan, China, India, South Korea, Australia Market drivers Adoption of minimally-invasive devices. Increase in medical aesthetic procedures. Developments in cosmetic surgery using laser technology. Rise in prevalence of obesity. Rise in medical tourism. Increase in demand for breast augmentation surgeries. Additional Insights: Global demand for medical aesthetic and cosmetic surgery procedures remains strong, with the U.S., Brazil, Japan, Italy, and Mexico the top five countries for total procedures performed. In 2023, the total number of surgical and non-surgical aesthetic procedures increased by 3.4%, reaching approximately 34.9 million worldwide . Breast augmentation continues to lead as the most commonly performed cosmetic surgery, accounting for 16.0% of all surgical procedures, followed by liposuction (15.1%), eyelid surgery (12.1%), rhinoplasty (8.4%), and abdominoplasty (7.6%). Women account for nearly 85.5% of all surgical cosmetic procedures performed worldwide. Market leaders include: AbbVie Inc. Alma Lasers Bausch Health Companies Inc. Candela Corp. Cutera Inc. Cynosure Lutronic Spa Implantech Johnson & Johnson Lumenis Be Ltd. Medytox Merz Pharma Photomedex Tiger Biosciences Venus Concept Get your copy of the report directly from BCC Research. To request more information or complete your purchase, connect with us at [email protected]. About BCC Research BCC Research market research reports provide objective, unbiased measurement and assessment of market opportunities. Our experienced industry analysts' goal is to help you make informed business decisions free of noise and hype. For media inquiries, email [email protected] or visit our media page for access to our market research library. Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Yahoo
5 hours ago
- Yahoo
Lung Cancer Screening Market to Reach USD 7.44 Billion by 2032, Driven by LDCT Adoption and Growing High-Risk Population
Global Lung Cancer Screening Market Forecast (2025–2032) Shows 9.32% CAGR, U.S. Market to Hit USD 2.21 Billion by 2032 Amid Early Detection Demand and Technological Advancements. Austin, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Lung Cancer Screening Market Size & Growth Analysis: According to SNS Insider, The Lung Cancer Screening Market was estimated at USD 3.66 billion in 2024 and is expected to reach USD 7.44 billion by 2032, at a CAGR of 9.32% during the forecast period of 2025-2032. The global lung cancer screening market growth is driven by the increasing prevalence of lung cancer and growing adoption of screening, initiatives to increase awareness about lung cancer, and the introduction of new and advanced products. Favorable governmental policies, rising healthcare infrastructure, and technological advancements are other factors driving Free Sample Report of the Lung Cancer Screening Market: The U.S. lung cancer screening market was estimated at USD 1.12 billion in 2024 and is expected to reach USD 2.21 billion by 2032, at a CAGR of 8.89% during the forecast period of 2025-2032 The U.S. dominated the North American lung cancer screening market, driven by robust policy support and early uptake of low-dose computed tomography (LDCT) among the eligible high-risk population of 50 to 80-year-olds with a smoking history of 20+ pack-years under updated USPSTF guidelines. Segmentation & Regional Highlights By Modality, the LDCT Segment Dominates the Lung Cancer Screening Market in 2024 The low-dose computed tomography (LDCT) segment held the largest share of the lung cancer screening market in 2024 with a 61.2% market share owing to high accuracy, non-invasive nature, and support by such as the U.S. Preventive Services Task Force (USPSTF) and other major health societies. LDCT allows early lung cancer diagnosis in high-risk patients and dramatically improves survival. Incorporation of cancer screening and insurance coverage has facilitated adoption, particularly in the developed world. By Cancer Type, the Non-Small Cell Lung Cancer (NSCLC) Segment Dominates the Market and is Witnessing High Growth Over the Forecast Period Non-small cell lung cancer (NSCLC) segment held a major share of the lung cancer screening market in 2024 as a result of the high prevalence of NSCLC among the population, which accounts for nearly 85% of all lung cancer cases around the globe. NSCLC is slow compared to small cell lung cancer, making it possible for more cases to be found early and diagnosed during screening. The demand for NSCLC screening has also increased with the development of targeted therapies and biomarkers for NSCLC. The 60–69 Years Segment Dominated the Lung Cancer Screening Market by Age Group The 60–69 years age group dominated the Lung Cancer Screening Market in the year 2024, owing to the higher prevalence of lung cancer in this age group. Members of this group are usually longer-term smokers or have had more exposure to carcinogens, and are therefore at higher risk, justifying the need for regular screening. Many countries' medical guidelines give this age range priority for low-dose CT screening, which has driven an increase in use. Lung Cancer Screening Market in North America Led in 2024 with a 40.3% Market Share, APAC Poised to be the Fastest-Growing Regional Market. The lung cancer screening market in North America is driven by the well-developed healthcare system, early uptake of advanced screening technologies such as LDCT, and favorable reimbursement scenarios. Marked awareness of lung cancer, full-scale enforcement of national screening guidelines, and a strong position of key players provide additional prospects for regional supremacy. Screening programmes promoted by governmental institutions such as the U.S. Preventive Services Task Force (USPSTF) have increased the screening rates, especially in high-risk individuals, and the region has evolved into a global market leader. The Asia-Pacific lung cancer screening market is estimated to register the highest CAGR, on account of a rise in the incidence of lung cancer, increasing awareness, and the increasing healthcare expenditure in the region. China, India, Japan, and other countries are enhancing early cancer screening initiatives, expanding access to LDCT and biomarker testing. For a Personalized Briefing with Our Industry Analysts, Connect Now: Key Lung Cancer Screening Companies Profiled in the Report GE HealthCare Siemens Healthineers Philips Healthcare Canon Medical Systems Corporation Fujifilm Holdings Corporation Samsung Medison Co. Ltd. Carestream Health Shimadzu Corporation Vuno Inc. Zebra Medical Vision Aidoc Riverain Technologies Lunit Inc. Roche Diagnostics Illumina Inc. Guardant Health Exact Sciences Corporation Bio-Rad Laboratories CT Screening International and other players. Lung Cancer Screening Market Report Scope Report Attributes Details Market Size in 2024 US$ 3.66 billion Market Size by 2032 US$ 7.44 billion CAGR CAGR of 9.32% From 2025 to 2032 Base Year 2024 Forecast Period 2025-2032 Historical Data 2021-2023 Regional Analysis North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) Key Growth Drivers Growing incidence of lung cancer worldwide Increased public awareness and government-led screening programs Advancements in imaging technologies (e.g., AI-enabled CT scans) Rising demand for non-invasive and early-stage cancer detection Supportive reimbursement policies in the U.S. and Europe Unique Selling Propositions (USPs) of the Report: Country-level eligibility for the screening landscape Assists your company in prioritizing markets that have high potential opportunity by comparing age, risk, and reimbursement criteria for screening across countries. Adoption curves comparison: LDCT vs. new technologies Facilitates strategic planning by identifying lung cancer screening early adopters vs. laggards for LDCT and next-gen technologies, and helps to launch market entry timing. Biomarker Inclusion in Lung Screening Helps companies make R&D and partnership decisions by monitoring how molecular diagnostics are supplementing or undercutting traditional screening. RoS (Return on Screening) Modelling Measures the cost per site of value of your screening programs to enable XYZ Company to create a persuasive business case for customers or reimbursement agencies, or health authorities. Buy the Full Lung Cancer Screening Market Report (Single-User License) Now: About Us: SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world. CONTACT: Contact Us: Jagney Dave - Vice President of Client Engagement Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK) Email: info@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
